Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
280 Bio
San Francisco, California, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
280 Bio is a clinical-stage biotechnology company and a subsidiary of BridgeBio Pharma, focused on developing next-generation precision oncology therapies. The company's lead program, BBO-8520, is a first-in-class small molecule inhibitor designed to target the active (on) state of the KRAS G12C mutation. By binding to the active conformation, 280 Bio aims to overcome resistance mechanisms associated with first-generation KRAS inhibitors that only target the inactive state. The company leverages BridgeBio's centralized resources to accelerate the development of targeted therapies for patients with high unmet medical needs in cancer.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on 280 Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 280 Bio.